We retrospectively examined the potential effect on overall survival (OS) of delaying radiotherapy to administer neoadjuvant therapy in unresected glioblastoma patients.
Patients and methods
We compared OS in 119 patients receiving neoadjuvant therapy followed by standard treatment (NA group) and 96 patients receiving standard treatment without neoadjuvant therapy (NoNA group). The MaxStat package of R identified the optimal cut-off point for waiting time to radiotherapy.
OS was similar in the NA and NoNA groups. Median waiting time to radiotherapy after surgery was 13 weeks for the NA group and 4.2 weeks for the NoNA group. The longest OS was attained by patients who started radiotherapy after 12 weeks and the shortest by patients who started radiotherapy within 4 weeks (12.3 vs 6.6 months) (P = 0.05). OS was 6.6 months for patients who started radiotherapy before the optimal cutoff of 6.43 weeks and 19.1 months for those who started after this time (P = 0.005). Patients who completed radiotherapy had longer OS than those who did not, in all 215 patients and in the NA and NoNA groups (P = 0.000). In several multivariate analyses, completing radiotherapy was a universally favorable prognostic factor, while neoadjuvant therapy was never identified as a negative prognostic factor.
In our series of unresected patients receiving neoadjuvant treatment, in spite of the delay in starting radiotherapy, OS was not inferior to that of a similar group of patients with no delay in starting radiotherapy.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC–NCIC trial. Lancet Oncol. 2009;10:459–66.
Patil CG, Yi A, Elramsisy A, Hu J, Mukherjee D, Irvin DK, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg. 2012;117:705–11.
Jeremic B, Grujicic D, Antunovic V, Djuric L, Stojanovic M, Shibamoto Y. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol. 1994;21:177–85.
Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23(Suppl 10):x231–6.
Biagioli MC, Fernandez DC, Spiess PE, Wilder RB. Primary bladder preservation treatment for urothelial bladder cancer. Cancer Control. 2013;20:188–99.
Grossman SA, O’Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, et al. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol. 2003;21:1485–91.
Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus P, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol. 2007;25:1470–5.
Brada M, Ashley S, Dowe A, Gonsalves A, Huchet A, Pesce G, et al. Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. Ann Oncol. 2005;16:942–9.
Balana C, Lopez-Pousa A, Berrocal A, Yaya-Tur R, Herrero A, Garcia JL, et al. Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). J Neurooncol. 2004;70:359–69.
Hochberg F, Grossman SA, Mikkelsen T, Glantz M, Fisher JD, Piantadosi S. Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium. Neuro Oncol. 2000;2:29–33.
Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEFdagger. Ann Oncol. 2014;25:1442–7.
Balana C, De Las Penas R, Sepulveda JM, Gil-Gil MJ, Luque R, Gallego O, et al. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016;127:569–79.
Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J, et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol. 1997;15:3121–8.
Vinolas N, Gil M, Verger E, Villa S, Pujol T, Ceral L, et al. Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anticancer Drugs. 2002;13:163–7.
Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 2009;15:6258–66.
Balana C, Gil MJ, Perez P, Reynes G, Gallego O, Ribalta T, et al. Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study. Target Oncol. 2014;9:321–9.
Capdevila L, Cros S, Ramirez JL, Sanz C, Carrato C, Romeo M, et al. Neoadjuvant cisplatin plus temozolomide versus standard treatment in patients with unresectable glioblastoma or anaplastic astrocytoma: a differential effect of MGMT methylation. J Neurooncol. 2014;117:77–84.
Bauchet L, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010;12:725–35.
Graus F, Bruna J, Pardo J, Escudero D, Vilas D, Barcelo I, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008–2010 in Spain. Neuro Oncol. 2013;15(6):797–805.
Wen PY, Chang SM, Van den Bent MJ, Vogelbaum MA, Macdonald DR, Lee EQ. Response assessment in neuro-oncology clinical trials. J Clin Oncol. 2017;35:2439–49.
Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015;17:1188–98.
Balana C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, et al. Pseudoprogression as an adverse event of glioblastoma therapy. Cancer Med. 2017;6:2858–66.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, et al. Radiation therapy for glioblastoma: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for radiation oncology guideline. J Clin Oncol. 2017;35:361–9.
Stensjoen AL, Solheim O, Kvistad KA, Haberg AK, Salvesen O, Berntsen EM. Growth dynamics of untreated glioblastomas in vivo. Neuro Oncol. 2015;17:1402–11.
Burnet NG, Jena R, Jefferies SJ, Stenning SP, Kirkby NF. Mathematical modelling of survival of glioblastoma patients suggests a role for radiotherapy dose escalation and predicts poorer outcome after delay to start treatment. Clin Oncol (R Coll Radiol). 2006;18:93–103.
Majos C, Cos M, Castaner S, Pons A, Gil M, Fernandez-Coello A, et al. Preradiotherapy MR imaging: a prospective pilot study of the usefulness of performing an MR examination shortly before radiation therapy in patients with glioblastoma. AJNR Am J Neuroradiol. 2016;37:2224–30.
Merkel A, Soeldner D, Wendl C, Urkan D, Kuramatsu JB, Seliger C, et al. Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials. J Neurooncol. 2017;132:249–54.
Alnaami I, VanderPluym J, Murtha A, Walling S, Mehta V, Gourishankar S, et al. The potential impact of delayed radiation therapy on patients with glioblastoma. Can J Neurol Sci. 2013;40:790–4.
Valduvieco I, Verger E, Bruna J, Caral L, Pujol T, Ribalta T, et al. Impact of radiotherapy delay on survival in glioblastoma. Clin Transl Oncol. 2013;15:278–82.
Noel G, Huchet A, Feuvret L, Maire JP, Verrelle P, Le Rhun E, et al. Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. J Neurooncol. 2012;109:167–75.
Seidlitz A, Siepmann T, Lock S, Juratli T, Baumann M, Krause M. Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. Radiat Oncol. 2015;10:172.
Lai R, Hershman DL, Doan T, Neugut AI. The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme. Neuro Oncol. 2010;12:190–8.
Blumenthal DT, Won M, Mehta MP, Curran WJ, Souhami L, Michalski JM, et al. Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol. 2009;27:733–9.
Loureiro LV, Victor Eda S, Callegaro-Filho D, Koch Lde O, Pontes Lde B, Weltman E, et al. Minimizing the uncertainties regarding the effects of delaying radiotherapy for glioblastoma: a systematic review and meta-analysis. Radiother Oncol. 2016;118:1–8.
Murray D, Mirzayans R, Scott AL, Allalunis-Turner MJ. Influence of oxygen on the radiosensitivity of human glioma cell lines. Am J Clin Oncol. 2003;26:e169–77.
This work was supported by Fundació La Marató TV3 (665/C/2013) (http://www.ccma.cat/tv3/marato/projectes-financats/2012/231/) and a Grant of the Spanish Instituto Carlos III (FISS-ICIII: project EC08/00071). Financial support and logistics assistance for the study GENOM 008 study were provided by Pfizer and for the GENOM 009 study by Roche and MSD. The funding bodies were not involved in patient recruitment, data collection, data interpretation, or the decision to publish. The corresponding author assumes all responsibility for the data.
Conflict of interest
Carmen Balaña declares an advisory position for AbbVie and Amgen and financial support for attending symposia of Pharmamar. The remaining authors declare that they have no conflict of interest.
The studies were approved by the Ethics Committee of each participating hospital.
Written informed consent was obtained from all patients before registration in trials/projects of the GEINO and GLIOCAT groups.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Balaña, C., Estival, A., Teruel, I. et al. Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients. Clin Transl Oncol 20, 1529–1537 (2018). https://doi.org/10.1007/s12094-018-1883-7
- Radiotherapy delay
- Neoadjuvant therapy
- Waiting time to radiotherapy
- Overall survival